Roger J. Lias

Avid Bioservices, Inc. provides specialized cell cultures for biotechnology testing. Its services include cell line optimization, cell culture and purification process development, protein characterization, process optimization, scale-up and validation, cGMP clinical and commercial manufacturing, bulk filling, aseptic filling, analytical assay development, method qualification and validation, QC release and stability testing and regulatory strategy and submission. The company was founded by Steven W. King in 2001 and is headquartered in Tustin, CA.

Part of Pharmaron Beijing Co., Ltd., Allergan Biologics Ltd. develops biologics products. The company is based in Liverpool, UK. The British company was founded in 2002 by Bernard Chan. Allergan Biologics was acquired by Pharmaron Biologics (UK) Holdings Ltd. from AbbVie, Inc. on April 30, 2021 for $165.95 million.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Stelis Biopharma Pvt Ltd. develops and manufactures pharmaceutical products. The company was founded in 2007 and is headquartered in Bangalore, India.

Part of AbbVie, Inc., Eden Biodesign LLC is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Durham, NC.

Wheeler Bio, Inc. is a biomanufacturing company based in the biomanufacturing metro of Oklahoma City, OK. Wheeler Bio's technology platform, Portable CMC™, simplifies the path between drug discovery and clinical manufacturing, providing a new bridge for translating discoveries to first-in-human trials. The company's hub-and-spoke operational model, integrated with biotechs and discovery CROs, revolutionizes the speed of drug development. Wheeler Bio offers a different CDMO model to help innovators go faster with candidates, accelerating processes for plasmids, cell lines, characterization, and more. The company's biologics CDMO facility offers protein expression, cell line development, process development, analytical development, and material supply and testing capabilities. The company was founded by a team of industry experts and strategic investors, led by Jesse McCool who has been the CEO since incorporation.